These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30181842)

  • 1. Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy.
    Arshad S; Singh A; Awasthi NP; Kumari S; Husain N
    Ther Adv Hematol; 2018 Aug; 9(8):213-226. PubMed ID: 30181842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum TNF-
    Susanah S; Raspati H; Sari NM; Rakhmilla LE; Sribudiani Y; Moestopo O; Sinaga P; Idjradinata P; Maskoen AM
    Biomed Res Int; 2021; 2021():6483490. PubMed ID: 34778454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitor; An Uncommon But Vexing Challenge In North Indian Patients With Hemophilia A.
    Ray D; Kumar N; Hans C; Kler A; Jain R; Bansal D; Trehan A; Jain A; Malhotra P; Ahluwalia J
    Indian J Hematol Blood Transfus; 2022 Oct; 38(4):703-709. PubMed ID: 36258733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2).
    Nogami K; Taki M; Matsushita T; Kojima T; Oka T; Ohga S; Kawakami K; Sakai M; Suzuki T; Higasa S; Horikoshi Y; Shinozawa K; Tamura S; Yada K; Imaizumi M; Ohtsuka Y; Iwasaki F; Kobayashi M; Takamatsu J; Takedani H; Nakadate H; Matsuo Y; Matsumoto T; Fujii T; Fukutake K; Shirahata A; Yoshioka A; Shima M;
    Haemophilia; 2022 Sep; 28(5):745-759. PubMed ID: 35689832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailored prophylaxis in children with severe hemophilia: A four-year Iranian study.
    Baghaipour M; Salimi T; Bahoush G; Jazebi M; Ala F; Azizi Saraji A; Dorgalaleh A; Moazezi Nekoei Asl SS; Mohamadamini M; Tabibian S
    Transfus Apher Sci; 2021 Dec; 60(6):103212. PubMed ID: 34257016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modified Bethesda, modified Nijmegen and blank assays for coagulation factor VIII inhibitor detection and factors affecting the results].
    Feng HM; Li Q; Xu WS; Chen DM; Zheng L
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):592-5. PubMed ID: 27113194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.
    Batlle J; Gómez E; Rendal E; Torea J; Lourés E; Couselo M; Vila P; Sedano C; Tusell X; Magallón M; Quintana M; González-Boullosa R; López-Fernández MF
    Ann Hematol; 1996 May; 72(5):321-6. PubMed ID: 8645745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?
    Sherief LM; Gaber OA; Youssef HM; Sherbiny HS; Mokhtar WA; Ali AAA; Kamal NM; Abdel Maksoud YH
    Ital J Pediatr; 2020 Sep; 46(1):129. PubMed ID: 32928254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy.
    Giles AR; Rivard GE; Teitel J; Walker I
    Transfus Sci; 1998 Jun; 19(2):139-48. PubMed ID: 10187039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
    Bray GL; Gomperts ED; Courter S; Gruppo R; Gordon EM; Manco-Johnson M; Shapiro A; Scheibel E; White G; Lee M
    Blood; 1994 May; 83(9):2428-35. PubMed ID: 8167332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful management of total knee replacement in a high responder hemophilia patient with a history of inhibitor.
    Dolatkhah R; Bazavar MR; Poureisa M; Asvadi Kermani I; Vaez Gharamaleki J; Sanaat Z; Eivazi Ziaei J; Nikanfar A; Esfahani A; Chavoshi SH
    Iran Red Crescent Med J; 2013 Jan; 15(1):18-20. PubMed ID: 23486529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
    Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
    Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of factor VIII inhibitors among Afghan patients with hemophilia A: a first report.
    Mousavi SH; Mesbah-Namin SA; Rezaie N; Jazebi M; Zeinali S
    Blood Coagul Fibrinolysis; 2018 Dec; 29(8):697-700. PubMed ID: 30439768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
    Oldenburg J; Shima M; Kruse-Jarres R; Santagostino E; Mahlangu J; Lehle M; Selak Bienz N; Chebon S; Asikanius E; Trask P; Mancuso ME; Jiménez-Yuste V; von Mackensen S; Levy GG
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28474. PubMed ID: 32776489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan.
    Shinozawa K; Yada K; Kojima T; Nogami K; Taki M; Fukutake K; Yoshioka A; Shirahata A; Shima M;
    Thromb Haemost; 2021 May; 121(5):603-615. PubMed ID: 33254277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.